$16.17
1.42%
Downside
Day's Volatility :5.82%
Upside
4.46%
53.12%
Downside
52 Weeks Volatility :64.65%
Upside
24.58%
Period | Greenwich Lifesciences Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 26.68% | 6.5% | 0.0% |
6 Months | 90.6% | 7.1% | 0.0% |
1 Year | 85.28% | 9.8% | 0.0% |
3 Years | -59.47% | 14.2% | -20.2% |
Market Capitalization | 200.3M |
Book Value | $0.4 |
Earnings Per Share (EPS) | -0.71 |
Wall Street Target Price | 36.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -69.02% |
Return On Equity TTM | -109.97% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -9.6M |
Diluted Eps TTM | -0.71 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.75 |
EPS Estimate Next Year | -0.7 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.2 |
What analysts predicted
Upside of 122.63%
Sell
Neutral
Buy
Greenwich Lifesciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Greenwich Lifesciences Inc | -2.81% | 90.6% | 85.28% | -59.47% | 232.4% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Greenwich Lifesciences Inc | NA | NA | NA | -0.75 | -1.1 | -0.69 | NA | 0.4 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Greenwich Lifesciences Inc | Buy | $200.3M | 232.4% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Greenwich Lifesciences Inc
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 246.0%
Vanguard Group Inc
Millennium Management LLC
Geode Capital Management, LLC
BlackRock Inc
Goldman Sachs Group Inc
Renaissance Technologies Corp
Organization | Greenwich Lifesciences Inc |
Employees | 3 |
CEO | Mr. Snehal S. Patel |
Industry | Health Technology |
A Spac I Acquisition Corp
$16.17
-2.71%
Keyarch Acquisition Corp
$16.17
-2.71%
Connexa Sports Technologies Inc
$16.17
-2.71%
Us Value Etf
$16.17
-2.71%
First Wave Biopharma Inc
$16.17
-2.71%
Global X Msci Next Emerging
$16.17
-2.71%
Fat Projects Acquisition Corp
$16.17
-2.71%
Capital Link Global Fintech
$16.17
-2.71%
Applied Uv Inc
$16.17
-2.71%